Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study
The addition of imeglimin to DPP-4i significantly improved glycemic control and glycemic variability, based on increased glucose-induced insulin secretion, indicating its potential as a therapeutic option for patients with T2D.
Authors
- Fukumi Yoshikawa (ORCID: https://orcid.org/0000-0001-5320-2616)
- Genki Sato
- Hiroshi Uchino (ORCID: https://orcid.org/0000-0001-9282-918X)
- Masahiko Miyagi (ORCID: https://orcid.org/0000-0003-3827-3568)
- Yoko Iwata
- Takahisa Hirose
- Ayako Fuchigami (ORCID: https://orcid.org/0009-0004-8461-2246)
- Atsushi Itsukaichi
Institutions
- Toho University (JP)
Publication Details
- Journal
- Diabetes Metabolic Syndrome and Obesity
- Published
- 2025-01-01
- DOI
- https://doi.org/10.2147/dmso.s495930
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59